Pharmacoepidemiology and drug safety
-
Pharmacoepidemiol Drug Saf · May 2017
Defined daily doses (DDD) do not accurately reflect opioid doses used in contemporary chronic pain treatment.
To assess how well the defined daily dose (DDD) metric reflects opioid utilisation among chronic non-cancer pain patients. ⋯ For many opioids, there are key differences between the actual doses used in clinical practice and the WHO's DDDs. The interpretation of opioid utilisation studies using population-level DDDs may be limited, and a recalibration of the DDD for many opioids or the reporting of opioid utilisation in oral morphine equivalent doses is recommended. Copyright © 2017 John Wiley & Sons, Ltd.
-
Pharmacoepidemiol Drug Saf · May 2017
Assessing the accuracy of opioid overdose and poisoning codes in diagnostic information from electronic health records, claims data, and death records.
The purpose of this study is to assess positive predictive value (PPV), relative to medical chart review, of International Classification of Diseases (ICD)-9/10 diagnostic codes for identifying opioid overdoses and poisonings. ⋯ Opioid poisoning codes have a predictive value of 81% to identify opioid overdoses, suggesting ICD opioid poisoning codes can be used to monitor overdose rates and evaluate interventions to reduce overdose. Further research to assess sensitivity, specificity, and negative predictive value are ongoing. Copyright © 2017 John Wiley & Sons, Ltd.
-
Pharmacoepidemiol Drug Saf · May 2017
Antiemetic use among pregnant women in the United States: the escalating use of ondansetron.
To examine ondansetron use in pregnancy in the context of other antiemetic use among a large insured United States population of women delivering live births. ⋯ We observed a marked increase in ondansetron use by study year, prescribed to nearly one-quarter of insured pregnant women in 2014, occurring in conjunction with decreased use of promethazine and metoclopramide. Given the widespread use of ondansetron in pregnancy, data establishing product efficacy and methodologically rigorous evaluation of post-marketing safety are needed. Published 2017. This article is a U.S. Government work and is in the public domain in the USA.
-
Pharmacoepidemiol Drug Saf · May 2017
Sample size of the reference sample in a case-augmented study.
The case-augmented study, in which a case sample is augmented with a reference (random) sample from the source population with only covariates information known, is becoming popular in different areas of applied science such as pharmacovigilance, ecology, and econometrics. In general, the case sample is available from some source (for example, hospital database, case registry, etc.); however, the reference sample is required to be drawn from the corresponding source population. ⋯ In this work, we address the minimum sample size calculation and discuss related issues. Copyright © 2017 John Wiley & Sons, Ltd.